10-Q: Harrow Inc. Reports Strong Q1 Revenue Growth Driven by Branded Product Sales

Harrow Inc. saw a significant increase in revenue during the first quarter of 2024, primarily driven by growth in its branded ophthalmology product sales.

Summary

• Harrow Inc. reported a net loss of $13.565 million for the first quarter of 2024, compared to a net loss of $6.643 million for the same period in 2023.
• The company's total revenue increased to $34.587 million in Q1 2024, up from $26.103 million in Q1 2023.
• Product sales, net, rose to $34.508 million in Q1 2024 from $20.453 million in Q1 2023.
• Other revenues decreased significantly to $79,000 in Q1 2024 from $5.650 million in Q1 2023, due to the end of profit transfers from acquired products.
• The company's gross profit increased to $24.034 million in Q1 2024 from $17.832 million in Q1 2023.
• Operating expenses increased to $30.962 million in Q1 2024 from $16.622 million in Q1 2023, driven by higher selling, general, and administrative costs.
• Research and development expenses also increased to $2.149 million in Q1 2024 from $734,000 in Q1 2023.
• The company's cash and cash equivalents decreased to $68.538 million at the end of Q1 2024 from $74.085 million at the end of 2023.
• Harrow sold its remaining interest in Eton Pharmaceuticals in April 2024 for net proceeds of $5.51 million.

Sentiment

Score: 5

Explanation: The document shows strong revenue growth and strategic moves, but the increased net loss and operating expenses are concerning. The company is in a growth phase with some risks.

Positives

• The company experienced significant revenue growth, primarily driven by branded product sales.
• Gross profit and gross margin both increased year-over-year.
• Harrow successfully launched VEVYE in the U.S. market.
• The company secured a licensing agreement with Apotex for the Canadian market.
• CMS clarified the billing policy for IHEEZO, which should improve reimbursement.

Negatives

• The company reported a net loss of $13.565 million for Q1 2024, which is larger than the $6.643 million loss in Q1 2023.
• Other revenues decreased significantly due to the end of profit transfers from acquired products.
• Operating expenses increased substantially, driven by higher selling, general, and administrative costs.
• Research and development expenses also increased significantly.
• Cash and cash equivalents decreased by $5.547 million during the quarter.

Risks

• The company is subject to regulatory standards that could impact its ability to sell certain products.
• The company relies on a limited number of suppliers for active pharmaceutical ingredients.
• A single customer accounts for a significant portion of the company's accounts receivable.
• The company has a history of net losses and may require additional financing to support its operations.
• The company is involved in ongoing legal proceedings, which could have a material adverse effect on its financial results.

Future Outlook

The company believes its current cash position and funds generated from operations will be sufficient to sustain planned operations for at least the next 12 months. They may also consider the sale of certain assets. The company plans to continue to pursue development and commercialization opportunities for its ophthalmology assets.

Management Comments

• The company believes it has built a tangible and intangible infrastructure that will allow it to scale revenues efficiently in the near and long-term.
• Management believes that cash and cash equivalents of $68,538,000 at March 31, 2024, in addition to net proceeds received from the sale of our Eton investment in April 2024, will be sufficient to sustain our planned level of operations and capital expenditures for at least the next 12 months.

Industry Context

The company operates in the competitive eyecare pharmaceutical market. The launch of VEVYE and the licensing agreement with Apotex are strategic moves to expand market reach and product offerings. The clarification from CMS regarding IHEEZO billing is a positive development for the company's reimbursement prospects.

Comparison to Industry Standards

• Harrow's revenue growth in Q1 2024 is strong compared to some of its peers in the pharmaceutical industry, particularly those focused on branded products.
• The increase in operating expenses is a concern, as many pharmaceutical companies are focused on cost control.
• The net loss is significant, and the company will need to demonstrate a path to profitability to be competitive with more established pharmaceutical companies.
• The company's reliance on a single customer for a large portion of its accounts receivable is a risk that is not typical for larger, more diversified pharmaceutical companies.
• The company's debt levels are high, which is not uncommon for growth-stage pharmaceutical companies, but it does increase the risk profile.

Legal Proceedings

• ImprimisRx, LLC, a subsidiary of the Company, is involved in a lawsuit against Ocular Science, Inc. and OSRX, Inc. for copyright infringement, trademark infringement, unfair competition and false advertising.
• OSRX has counterclaims alleging ImprimisRx, LLC is violating the Lanham Act with false advertising.
• Both parties are seeking damages from the other, and the trial is expected to take place in August 2024.

Related Party Transactions

• The company has a non-controlling equity interest in Melt Pharmaceuticals, Inc. and has entered into various agreements with them.
• The company's CEO, Mark L. Baum, is a member of the Melt board of directors.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss, but encouraged by the revenue growth.
• Employees may benefit from the company's growth and expansion.
• Customers may benefit from the company's expanded product offerings.
• Suppliers may benefit from the company's increased sales and production.
• Creditors may be concerned about the company's increased debt levels.

Next Steps

• The company will continue to focus on growing sales of its branded products.
• The company will work to optimize pricing and reimbursement for its products.
• The company will continue to pursue development and commercialization opportunities for its ophthalmology assets.
• The company will monitor the impact of the CMS clarification on IHEEZO billing.
• The company will continue to manage its debt and cash flow.

Key Dates

Keywords

ophthalmic pharmaceuticals, branded products, compounding, revenue growth, net loss, VEVYE, IHEEZO, Apotex, CMS, operating expenses